Financial Performance - The company's operating revenue for Q1 2021 was ¥821,082,483.69, representing a 3.44% increase compared to ¥793,742,204.43 in the same period last year[9]. - Net profit attributable to shareholders was ¥129,356,741.25, a 35.22% increase from ¥95,666,199.21 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥99,513,713.36, up 25.12% from ¥79,533,640.22 in the previous year[9]. - Basic earnings per share increased by 53.85% to ¥0.20 from ¥0.13 in the same period last year[9]. - The weighted average return on equity rose to 3.25%, an increase of 0.62 percentage points from 2.63%[9]. - Total operating revenue for the current period reached ¥821,082,483.69, an increase from ¥793,742,204.43 in the previous period, representing a growth of approximately 3.4%[65]. - Net profit for the current period was ¥129,071,948.22, compared to ¥96,502,982.74 in the previous period, reflecting a significant increase of approximately 33.7%[70]. - Total comprehensive income for the current period was ¥129,214,477.34, compared to ¥96,753,682.92 in the previous period, reflecting an increase of approximately 33.4%[70]. - Total comprehensive income for the current period was ¥76,332,075.95, compared to ¥69,585,952.89 in the previous period[77]. Cash Flow - The net cash flow from operating activities decreased by 33.08% to ¥81,555,730.34 from ¥121,862,146.77 in the previous year[9]. - Net cash flow from investing activities increased by 170.21% year-on-year, mainly due to increased cash received from investment recoveries[26]. - The net increase in cash and cash equivalents rose by 39.22% year-on-year, primarily due to increased cash received from investment recoveries[26]. - The ending balance of cash and cash equivalents increased by 102.09% year-on-year, mainly due to increased cash received from investment recoveries[29]. - Cash flow from operating activities generated a net amount of ¥81,555,730.34, down 33.1% from ¥121,862,146.77 in the previous period[81]. - Cash flow from investing activities showed a net inflow of ¥195,229,381.21, compared to a net outflow of ¥278,056,622.69 in the previous period[81]. - Cash and cash equivalents at the end of the period totaled ¥985,479,476.64, an increase from ¥487,655,058.71 at the end of the previous period[84]. - The company received ¥550,000,000.00 from investment recoveries, up from ¥389,161,518.55 in the previous period[81]. - Operating cash flow net amount increased to ¥121,599,921.00 from a negative ¥51,961,385.83 in the previous period, representing a significant turnaround[85]. - Total cash inflow from operating activities reached ¥808,374,540.95, up 68.1% from ¥480,629,605.57 in the prior period[85]. - Cash outflow from investment activities decreased to ¥240,173,391.10 from ¥616,806,029.96, indicating improved cash management[88]. - Net cash flow from investment activities was ¥266,435,348.62, a recovery from a negative cash flow of ¥188,871,161.12 in the previous period[88]. - Cash and cash equivalents at the end of the period totaled ¥837,492,064.79, up from ¥166,502,649.52, marking a substantial increase[88]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,606,221,217.38, a decrease of 1.06% from ¥5,666,246,990.95 at the end of the previous year[9]. - Total liabilities decreased from ¥1,733,577,519.82 to ¥1,520,220,086.55, a decline of approximately 12.30%[53]. - Current liabilities decreased from ¥1,546,858,959.40 to ¥1,313,365,004.32, a decline of approximately 15.08%[53]. - Total equity increased from ¥3,932,669,471.13 to ¥4,086,001,130.83, an increase of approximately 3.90%[56]. - Total assets decreased from ¥5,666,246,990.95 to ¥5,606,221,217.38, a decline of approximately 1.06%[56]. - Non-current assets increased from ¥2,541,232,696.18 to ¥2,802,370,726.20, an increase of approximately 10.27%[56]. - Cash and cash equivalents increased from ¥637,623,564.83 to ¥878,592,449.86, an increase of approximately 37.83%[57]. - Accounts receivable increased from ¥122,751,491.60 to ¥190,667,560.68, an increase of approximately 55.31%[57]. - Inventory increased from ¥143,558,211.15 to ¥153,597,506.33, an increase of approximately 6.67%[57]. - Long-term equity investments remained stable at ¥1,177,544,358.03, showing a slight increase from ¥1,177,044,358.03[60]. - Other non-current assets increased significantly from ¥149,669,034.48 to ¥306,075,291.12, an increase of approximately 104.00%[60]. - The company reported a total liability of CNY 1,357,757,439.20, with current liabilities at CNY 1,200,857,380.97 and non-current liabilities at CNY 156,900,058.23[99]. Investments and Funding - The company plans to raise a total of 500 million yuan through a non-public stock issuance to fund projects aimed at enhancing production capacity and digital workshop construction[30]. - The company utilized 19 million yuan of idle raised funds and 98 million yuan of idle self-owned funds for entrusted financial management[38]. - The company has no violations regarding external guarantees during the reporting period[39]. - The company’s long-term equity investments were valued at CNY 1,177,044,358.03, reflecting its commitment to strategic investments[99]. - The company received cash from investment recovery of ¥490,000,000.00, an increase from ¥389,161,518.55 in the previous period[88]. Research and Development - Research and development expenses rose to ¥77,253,712.63 from ¥66,227,053.39, indicating an increase of about 16.0%[68]. - Research and development expenses rose to ¥41,537,942.56, up 12.8% from ¥36,959,346.77 in the previous period[74]. Other Financial Metrics - The company reported a financial expense income of -¥6,726,788.98, compared to -¥2,842,619.09 in the previous period, indicating a worsening of financial expenses[68]. - Other income decreased from ¥21,856,411.09 to ¥14,653,506.07, a decline of approximately 33.0%[68]. - The company has not audited its first-quarter report for 2021, indicating a potential area for investor scrutiny[102].
京新药业(002020) - 2021 Q1 - 季度财报